Stanford University School of Medicine
Stanford, California, 94305, United States
NCT Number: NCT00186680
Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.
Looking for future studies?
Notify Me19 year–70 year
All sexes
Interventional
Phase 1 / Phase 2
Stanford, California, 94305, United States
Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- stage IV breast cancer
Stanford University
Other
Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00043472
Adnexal Diseases, Breast Cancer
Bethesda, Maryland, United States
View Trial DetailsNCT00469339
Breast Cancer, Breast Diseases
Houston, Texas, United States
View Trial DetailsNCT00006421
Breast Cancer, Breast Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT02206984
Breast Cancer, Breast Diseases
Birmingham, Alabama, United States
View Trial Details